

- Proteus* spp., 1033
Proteus spp. infections, **1033**
 antibiotic resistance in, 934, 1033–1034
 clinical features of, 1033
 diagnosis of, 1033
 epidemiology of, 1025
 renal abscess, 851
 treatment of, 1033–1034
 urinary tract, 862, 1033, 1871
- Prothrombin, 402f
 Prothrombin complex concentrate, 735, 739
 Prothrombin deficiency, 404, 733t
 Prothrombin gene mutations, 47, 404–405, 745
 Prothrombin inhibitors, 740
 Prothrombin time (PT), 732
 in acute viral hepatitis, 2016
 causes of abnormal values, 406t, 464t
 in coagulation disorders, 733t
 coagulation factors measured in, 405, 406f, 733f
 in hepatobiliary diseases, 1998, 1998t
 for monitoring warfarin therapy, 755
 in nutritional assessment, 464t
 prolonged, 283, 406t
 sensitivity of, 405
- Proton pump inhibitors (PPIs)
 adverse effects of, 263, 568, 644t, 1857, 1920–1921, 2218t
 for diarrhea, 272
 drug interactions of, 42t, 246e–3t, 1921
 for GERD, 263, 1908
 in *H. pylori* eradication, 263, 1041, 1042t
 hypergastrinemia and, 568
 for metabolic alkalosis, 322
 for NSAID-induced ulcer prophylaxis, 1924, 1924t
 for peptic ulcer disease, 276–277, 1920–1921, 1920t, 1924
 pharmacology of, 1921
 for stress-related mucosal injury, 1930
 for systemic mastocytosis, 2121
 for ZES, 568, 1929
- Protooncogenes, 101e–2
 Protoporphyrin, erythropoietic. *See* Erythropoietic protoporphyria
 Protoporphyrins, 390
 free erythrocyte, 2525
 red cell, 627f, 628
- Prototheca wickerhamii* infection, 926
- Protozoa
 adherence of, 145e–2t, 145e–3
 blood and tissue
Babesia. *See Babesia* spp.
Leishmania. *See Leishmania* spp.
Plasmodium. *See Plasmodium* spp.
Toxoplasma gondii. *See Toxoplasma gondii*
Trypanosoma. *See Trypanosoma* spp.
 entry into host, 145e–1
 free-living amebas
Acanthamoeba. *See Acanthamoeba* spp.
Balamuthia. *See Balamuthia* spp.
Naegleria. *See Naegleria* infection
 vs. helminthic parasites, 255e–1
 intestinal
Cryptosporidium. *See Cryptosporidium*/
 cryptosporidiosis
Cyclospora cayatanensis. *See Cyclospora*
cayatanensis/cyclosporiasis
Cystoisospora belli. *See Cystoisospora belli*/
 cystoisosporiasis
Entamoeba histolytica. *See Entamoeba*
histolytica
Giardia. *See Giardia* spp.
 Microsporidia. *See Microsporidia*/
 microsporidiosis
 laboratory identification of, 245e–4t, 245e–6t
 tissue invasion by, 145e–8
- Protriptyline, 190
Providencia infections, 1035, 1871
 Provirus, 225e–1
PROX1 gene, 1241t
 Proximal femoral neuropathy, 463e–5, 463e–5f
 Proximal interphalangeal (PIP) joint,
 rheumatoid arthritis in, 2136, 2137f
- Proximal myotonic myopathy (PROMM),
 462e–3, 462e–9, 462e–10
- Proximal tubule
 disorders involving, 332e–7t
 functions of, 332e–3f, 332e–6–8
 toxic injury to, 333e–4
- Prozone phenomenon, 391e–2, 1137
- PrP amyloid, 453e–1t
 PrP^{sc}, 453e–1, 453e–1f, 453e–1t, 453e–2f. *See also*
 Prion disease(s)
- PRPP (phosphoribosylpyrophosphate), 431e–2
 PRPP (phosphoribosylpyrophosphate)
 synthetase overactivity, 431e–3t,
 431e–5
- PrP^{sc}, 172t, 453e–1, 453e–1f, 453e–1t, 453e–2f.
See also Prion disease(s)
- PRRs. *See Pattern recognition receptors (PRRs)*
 PRRT (peptide radioreceptor therapy), 575
PRSSI gene mutations, 554, 2092, 2098
- Prucalopride, 274
 Prune juice, 62t
- Pruritus
 in atopic dermatitis, 345
 in biliary cirrhosis, 2061
 definition of, 340t
 drug-induced, 381
 in liver disease, 1991
 in scabies, 2744
 treatment of, 345
- Prussian blue, 81e–8f, 263e–6, 263e–6t, 472e–3
PS-1 gene mutations, 2601
PS-2 gene mutations, 2601
- PSA. *See Prostate-specific antigen (PSA)*
 PSC. *See Primary sclerosing cholangitis (PSC)*
 P-selectin, 276, 742
- Pseudallescheria boydii*, 491
 Pseudoachalasia, 1904
 Pseudoaldosteronism. *See Liddle's syndrome*
 (pseudoaldosteronism)
- Pseudoallergic fish poisoning, 2743
 Pseudoanemia, 636
 Pseudoaneurysm(s)
 aortic, 289e–3, 1637
 pancreatic, 2095f, 2097
 pericardial, 1610
- Pseudoappendicitis, 1077
 Pseudoarthrosis, 2171
 Pseudoathetosis, 158
 Pseudobulbar palsy, 154
 Pseudocholinesterase, 34t
 Pseudocowpox, 220e–1t
 Pseudocyst(s), pancreatic, 2093t, 2097
 Pseudodementia, 2608, 2715
 Pseudodiarrhea, 265
 Pseudodiverticulosis, esophageal, 1903, 1903f
 Pseudodominance, 438
 Pseudoephedrine
 adverse effects of, 305
 for allergic rhinitis, 2122, 2123f
 for bladder dysfunction, 2672
 contraindications to, 2122
 for orthostatic hypotension, 146
- Pseudogout, 372e–8t, 2235
 Pseudohalutosis, 242
 Pseudohermaphroditism
 female. *See* 46,XX disorders of sex
 development
 male. *See* 44,XY disorders of sex
 development
- Pseudo-Hurler polydystrophy, 432e–3t
 Pseudohyperkalemia, 309, 309t, 653, 1795
 Pseudohypertension, 1626
 Pseudohypertrophic muscular dystrophy. *See*
 Duchenne's muscular dystrophy
- Pseudohypoaldosteronism type I, 310, 332e–7t
 Pseudohypoaldosteronism type II (Gordon's
 syndrome)
 clinical features of, 310, 1620t
 genetic considerations in, 310, 332e–7t,
 332e–8, 1620t
 treatment of, 310
- Pseudohypoglycemia, 2430
 Pseudohypokalemia, 305
 Pseudohyponatremia, 301
- Pseudohypoparathyroidism (PHP)
 classification of, 2485, 2486t
 genetic considerations in, 430–431, 2476f,
 2486–2487, 2486f
 hypocalcemia and, 2485
 treatment of, 2487
- Pseudo-Kaposi's sarcoma, 367
- Pseudolymphoma (cutaneous lymphoid
 hyperplasia), 353, 364t, 365, 366
- Pseudomembrane(s)
 in diphtheria, 978, 978f
 in sulfur mustard exposure, 262e–3, 262e–3f
 in tularemia, 1068
- Pseudomembranous colitis, 855, 858, 858f, 1882f.
See also Clostridium difficile–associated
 disease
- Pseudomonas aeruginosa*, **1042**
 adherence of, 145e–2–3, 145e–2t
 antibiotic resistance in, 811, 934, 941t, 1047
 avoidance of host defenses by, 145e–3,
 145e–4f, 1043
 CTFR protein and, 145e–4f, 145e–5, 1043
 epidemiology of, 1043
 global considerations in, 1043
 growth after entry, 145e–4
 inflammatory response to, 1043
 laboratory identification of, 150e–2t, 1043
 motility of, 1043
 surface structures of, 145e–2f, 1043
 tissue injury by, 1043
 virulence factors of, 1043, 1043t
- Pseudomonas aeruginosa* infections, **1044**
 arthritis, 834, 835
 bacteremia, 1044, 1045t
 bone and joint, 1045t, 1046
 bronchiectasis, 1695
 burn-wound, 166e–1, 166e–2f, 166e–3, 1043
 in cancer patient, 486t, 487, 492
 cellulitis, 830
 chronic respiratory, 1044, 1045–1046
 CNS, 1045t, 1046
 in cystic fibrosis, 145e–4f, 145e–5, 1044, 1697
 diagnosis of, 343, 1043
 ear, 228–229, 1045t, 1046–1047
 ecthyma gangrenosum, 76e–12f, 135, 369, 830
 endovascular, 1045t, 1046
 epidemiology of, 1043
 in febrile neutropenia, 1045t, 1047
 folliculitis, 131t, 134, 356, 829, 1047
 global considerations in, 1045
 health care–associated pneumonia, 803t
 in HIV infection, 1047
 in lung abscess, 814
 mastoiditis, 231
 multidrug-resistant, 1045t, 1047
 nail, 1047
 ocular, 1045t, 1046
 osteomyelitis, 839, 840t, 841t, 844
 pathogenesis of, 1043–1044, 1043t
 perichondritis, 228
 pneumonia, 1044–1045, 1045t
 prevention of, 492
 risk factors for, 805
 sinusitis, 226
 in transplant recipient, 926
 treatment of, 808t, 830, 940t, 1045t
 urinary tract, 862, 1045t, 1047
 ventilator-associated pneumonia, 811, 812,
 915
- Pseudomonic acid. *See Mupirocin*
- Pseudoobstruction, intestinal. *See Intestinal*
 pseudoobstruction (Ogilvie's disease)
- Pseudoparaldehyde, 203, 203f
 Pseudoporphyria, 361t, 362, 379, 379f
 Pseudopseudohypoparathyroidism (PPHP), 430,
 2486f, 2486t
- Pseudoterranova decipiens*, 1416
 Pseudothrombocytopenia, 725, 726f
 Pseudotumor(s)
 in hemophilic arthropathy, 2241
 in IgG4-related disease, 391e–2
 orbital, 207
- Pseudotumor cerebri, 49, 203, 2293
 Pseudotumor syndrome, 733